AstraZeneca shares climbed about 6% on Wednesday after a senior source informed Reuters that there are "no discussions" between AstraZeneca and Bristol Myers Squibb regarding a potential combination. The statement directly contradicted earlier reports that had sparked a sharp repricing in both names.
The two companies involved are AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY). AZN bore the brunt of the market reaction earlier in the week, suffering an approximately 9% one-day drop on Monday when merger speculation first emerged. By contrast, BMY was widely seen as the likely beneficiary of any deal and had traded higher on the initial reports.
"There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the anonymous senior source told Reuters on Wednesday. That remark helped reverse part of AZN’s steep Monday decline, which had been the stock’s largest one-day fall since 2020 after reports published on Sunday, August 3 by the Financial Times. Reuters had earlier cited a separate person familiar with the situation who said that preliminary discussions had taken place, but Reuters said it was unable at that time to establish whether those conversations were still ongoing.
The magnitude of the alleged transaction had raised eyebrows across the investment community. Combined, AstraZeneca, with a market capitalization of about $264 billion, and BMS, at roughly $133 billion, would have created a company larger than the $99.6 billion BMS-Celgene deal of 2019, which had previously stood as the biggest pharmaceutical acquisition on record. Even so, several analysts questioned the strategic rationale for such a tie-up.
Jefferies, quoted by CNBC, called the proposal "more than a head scratcher," adding: "if there is one company that doesn’t need financial engineering, it’s AZ." Union Investment portfolio manager Markus Manns told Reuters the combination "does not make strategic or financial sense" and likened it to "the pharmaceutical industry’s equivalent of the FIFA privatisation moment."
Market responses illustrated that skepticism. AstraZeneca slid about 9% in London on Monday, making it the FTSE 100’s second-biggest decliner that session, while BMY shares rose roughly 6% in U.S. premarket trading the same day. The asymmetry in pricing suggested investors saw greater upside for BMY from a potential deal than benefits accruing to AZN shareholders.
Some investors voiced reservations about the strategic benefits for AstraZeneca. Lucy Coutts, investment director at JM Finn, told Reuters that "the only advantage for AstraZeneca in this rumoured combination with BMS seems to be to accelerate its U.S. footprint and sales" and observed that "BMS shareholders would be the winners of any combination with AZN."
Regulatory hurdles further complicated the prospect of a merger. Both companies compete directly in PD-(L)1 cancer immunotherapy, with BMS marketing Opdivo and AstraZeneca selling Imfinzi. They also hold the only two commercial anti-CTLA-4 agents on the market. Antitrust lawyer Andre Barlow of DBM Law Group, cited by FiercePharma, warned that significant regulatory divestitures would likely be required, increasing the complexity of any potential deal.
Compounding the view that a merger was unnecessary for AstraZeneca was the company’s own growth narrative. AstraZeneca posted second-quarter 2026 earnings per share of $2.63, ahead of a $2.48 consensus. The company is targeting $80 billion in annual revenue by 2030 and completed a direct listing on the New York Stock Exchange in June 2026. AstraZeneca has also committed $50 billion to U.S. research, development, and manufacturing investment by 2026. Together, those metrics and commitments were cited by analysts as providing a credible path to scale in the U.S. without taking on the regulatory and integration risks associated with a mega-merger.
With NYSE markets due to open Wednesday morning, U.S. investors were positioned to incorporate the Reuters denial into regular trading. The session would serve as a test of whether AZN’s rebound in London would translate into gains in New York and whether BMY would relinquish some or all of the deal-related premium it gained on Monday. Observers expected trading volume in both stocks to be elevated as participants reassessed valuations that had been repriced around a deal that, according to those close to the matter, was never actually on the table.
What to watch next
- Whether AZN’s London rebound sustains in U.S. trading.
- Whether BMY gives back the premarket gains it posted when merger speculation first surfaced.
- Trading volumes in both names as investors re-evaluate the earlier move driven by merger rumours.